- Home
- DDD vs CRVS Comparison
DDD vs CRVS Comparison
Compare DDD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDD
- CRVS
- Stock Information
- Founded
- DDD 1986
- CRVS 2014
- Country
- DDD United States
- CRVS United States
- Employees
- DDD N/A
- CRVS N/A
- Industry
- DDD Computer peripheral equipment
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- DDD Technology
- CRVS Health Care
- Exchange
- DDD Nasdaq
- CRVS Nasdaq
- Market Cap
- DDD 268.5M
- CRVS 206.5M
- IPO Year
- DDD N/A
- CRVS 2016
- Fundamental
- Price
- DDD $2.37
- CRVS $4.43
- Analyst Decision
- DDD Hold
- CRVS Strong Buy
- Analyst Count
- DDD 3
- CRVS 3
- Target Price
- DDD $3.50
- CRVS $16.33
- AVG Volume (30 Days)
- DDD 2.3M
- CRVS 1.4M
- Earning Date
- DDD 05-12-2025
- CRVS 05-08-2025
- Dividend Yield
- DDD N/A
- CRVS N/A
- EPS Growth
- DDD N/A
- CRVS N/A
- EPS
- DDD N/A
- CRVS N/A
- Revenue
- DDD $440,121,000.00
- CRVS N/A
- Revenue This Year
- DDD N/A
- CRVS N/A
- Revenue Next Year
- DDD $5.15
- CRVS N/A
- P/E Ratio
- DDD N/A
- CRVS N/A
- Revenue Growth
- DDD N/A
- CRVS N/A
- 52 Week Low
- DDD $1.71
- CRVS $1.75
- 52 Week High
- DDD $5.00
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- DDD 62.44
- CRVS 68.59
- Support Level
- DDD $1.92
- CRVS $3.17
- Resistance Level
- DDD $2.06
- CRVS $3.71
- Average True Range (ATR)
- DDD 0.12
- CRVS 0.23
- MACD
- DDD 0.08
- CRVS 0.08
- Stochastic Oscillator
- DDD 91.54
- CRVS 95.47
About DDD 3D Systems Corporation
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, on-demand manufacturing services, and digital design tools. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).